论文部分内容阅读
凝血第Ⅷ因子(FⅧ)是由包括26个外显子、长度为289kb组成的基因生成的蛋白质产物,刚合成时是由2000多个氨基酸组成的单肽链,在其从粗糙内质网移动到高尔基体时,被加工切去肽链中间部分,两端由Ca~(2+)连接在一起,其生化及生物学细节已有文献报道。采用沉淀技术可以使FⅧ制品达到治疗所必需的纯度,但是这些制品仅含0.1％有活性的抗血友病因子(AHF),即FⅧ蛋白。尽管有关FⅧ的生化知识对开发用于甲型血友病人替代治疗的制品并不是必需的,但对最终治愈血友病是必不可少的。
Coagulation Factor VIII (FVIII) is a protein product produced by a gene consisting of 26 exons and 289 kb in length. Upon initial synthesis, it is a single peptide chain consisting of more than 2000 amino acids and moves from its rough endoplasmic reticulum To the Golgi apparatus, it is processed to cut the middle part of the peptide chain, the two ends are connected by Ca2 +, and its biochemical and biological details have been reported in the literature. The precipitation technique allows F VIII preparations to reach the purity necessary for treatment, but these preparations contain only 0.1% active anti-haemophilia factor (AHF), the FⅧ protein. Although the biochemical knowledge of F Ⅷ is not essential for the development of products for substitution therapy for hemophilia A, it is essential for the eventual cure for hemophilia.